维普期刊资源整合服务平台（V6.5）

261篇 您的检索式：作者名="PLUTZKY J"

选中清除导出查看参考文献查看引证文献引用追踪共14页首页上一页第1页下一页末页 /14 跳转

	题名	作者	年代	出处	被引量
1	A review of metabolic and cardiovascular effects of oral antidiabetic agents:beyond glucose-level lowering显示文摘	Plutzky J Sobel BE	1999	J Cardiovasc Risk1999，6，：	1
2	Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors显示文摘	Lanfs U La Fata V Plutzky J	1998	Circulation1998，97，12：	1
3	Inflammation in Diabetes Mellitus:Role of Peroxisome Proliferator-Activated Receptor-Alpha and Peroxisome Proliferator-Activated Receptor-Gamma Agonists显示文摘	Libby P Plutzky J	2007	Am J Cardiol2007，99，4：	1
4	Meta-analysis demonstrates that Liraglutide,a once-daily human GLP-1 analogue,significantly reduces lipids ang other markers of cardiovascular risk in type 2 diabetes显示文摘	Plutzky J Garber A Toft AD	2009	Diabetologia2009，52，1：	1
5	The pathologic continuum of dia-betic vascular disease显示文摘	Orasanu G and Plutzky J	2009	J Am Coll Cardiol2009，53，5：	1
6	Upregulation of endothelial nitric oxide synthase by HMG-COA reductase inhibitors显示文摘	Ulrich L Fata VL Plutzky J	1998	Circulation1998，97，2：	1
7	Upregulation of endothelial nitric oxide synthase by HMC-CoA reductase inhibitors显示文摘	Laufs U La-Fata F Plutzky J	1998	Circulation1998，97，：	1
8	The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis显示文摘	Plutzky J	2003	Am J Cardiol2003，92，4：	1
9	Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors显示文摘	Laufs U Vito La Fata BA Plutzky J		0，，：	1
10	Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes显示文摘	Plutzky J Garber A Toft AD	2009	Diabetologia2009，52，1：	1
11	PPARs as therapeutic targents:reverse cardiology显示文摘	Plutzky J		0，，：	1
12	Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors 显示文摘	Fata VL Plutzky J	1998	Circulation1998，97，：	1
13	Plasminogen activator inhibitor-1 is reduced by the once-daily human glucagon-like peptide-1 analog liraglutide when used in the treatment of type 2 diabetes显示文摘	Plutzky J Poulter NR Falahati A	2009	Circulation2009，120，2：	1
14	Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhiditors 显示文摘	Lafata VL Plutzky J	1998	Circulation1998，97，：	1
15	PPARα in atherosclerosis and inflammation显示文摘	Zandbergen F Plutzky J	2007	Biochimica et biophysic a acta (BBA)-Molecular and Cell Biology of Lipids2007，1771，8：	1
16	Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors显示文摘	Laufs U La Fata V Plutzky J	1998	Circulation1998，97，12：	1
17	Meta-analysis demonstrates that liraglutide,a once-daily human GLP-1 analogue,significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes显示文摘	Plutzky J Garber A Toft AD	2009	Diabetologia2009，52，1：	1
18	Inflammtory pathways in atherosclerosis and acute coronary syndromes显示文摘	Plutzky J	2001	Am J Cardiol2001，88，8：	1
19	Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes 显示文摘	Plutzky J Graber A Toft A D	2009	Diabetologia2009，52，1：	1
20	Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors显示文摘	Laufs U La Fata V Plutzky J	1998	Circulation1998，97，：	1

返回顶部每页显示：

共14页首页上一页第1页下一页末页 /14 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示